News
CLNN
6.06
+4.66%
0.27
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials
TipRanks · 3d ago
Weekly Report: what happened at CLNN last week (0615-0619)?
Weekly Report · 5d ago
Weekly Report: what happened at CLNN last week (0608-0612)?
Weekly Report · 06/15 09:18
Weekly Report: what happened at CLNN last week (0601-0605)?
Weekly Report · 06/08 09:18
Weekly Report: what happened at CLNN last week (0525-0529)?
Weekly Report · 06/01 09:19
Weekly Report: what happened at CLNN last week (0518-0522)?
Weekly Report · 05/25 09:19
Clene Extends Note Maturities and Expands Equity Plan
TipRanks · 05/22 22:27
Clene stockholders approved 1 million-share increase to amended 2020 stock plan
PUBT · 05/22 20:38
Weekly Report: what happened at CLNN last week (0511-0515)?
Weekly Report · 05/18 09:19
Analysts Offer Insights on Consumer Goods Companies: Laird Superfood (LSF) and Clene (CLNN)
TipRanks · 05/15 13:41
Clene (CLNN) Gets a Buy from JonesTrading
TipRanks · 05/15 12:40
Canaccord Genuity Sticks to Their Buy Rating for Clene (CLNN)
TipRanks · 05/15 11:05
Roth says FDA approving Clene’s ALS treatment NDA a ‘long shot’
TipRanks · 05/14 19:55
Analyst Reiterates Buy on Advancing CNM-Au8 ALS Pathway and Funding Visibility; $31 Price Target Maintained
TipRanks · 05/14 16:46
Clene reports Q1 EPS (69c), consensus (70c)
TipRanks · 05/14 16:30
Clene GAAP EPS of -$0.69, revenue of $0.01M
Seeking Alpha · 05/14 13:12
Clene Q1 EPS $(0.69) Misses $(0.66) Estimate, Sales $15.000K Miss $35.064K Estimate
Benzinga · 05/14 12:39
Clene Extends Debt Maturities and Strengthens Cash Runway
TipRanks · 05/14 12:32
*Clene Expects to Submit NDA for CNM-Au8 Under the Accelerated Approval Pathway in 3Q >CLNN
Dow Jones · 05/14 12:11
Clene Q1 loss widens on warrant liability issuance costs
Reuters · 05/14 12:09
More
Webull provides a variety of real-time CLNN stock news. You can receive the latest news about Clene through multiple platforms. This information may help you make smarter investment decisions.
About CLNN
Clene Inc. is a clinical-stage pharmaceutical company, which is engaged in discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities that do not present in those same elements in bulk form. CNM-Au8, the lead drug asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals for the treatment of ALS, MS, and PD. CNM-Au8's mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is an antiviral and antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions in an aqueous solution to treat infectious disease and to provide immune support for symptom resolution.